Mononuclear Therapeutics Ltd (MonoTx™) in Hong Kong received American Association of Blood Banks (AABB) accreditation to carry out cellular therapy activities, including collection, processing, storage and distribution of umbilical cord blood stem cells, such as hematopoietic stem cells and mononuclear cells.
AABB did an intensive on-site assessment to determine that the technical and administrative performance meets or exceeds AABB standards. MonoTx™ joins similar AABB accredited top blood banking institutions in the United States and around the world that treat millions of patients with hematopoietic and other disorders.
“The AABB’s Accreditation procedures are voluntary”, MonoTx™ CEO Mr. Kenneth Giacin explained. “MonoTx™ sought AABB Accreditation because this program assists facilities around the world in achieving excellence by promoting a level of professional and technical expertise that contributes to quality performance and patient safety.”
The AABB’s Accreditation Program defines global recognized standards for collecting, processing, testing, distribution and administrating blood and cellular therapy products. AABB standards comply with the U.S. Code of Federal Regulations and other federal guidance documents. MonoTx™ primary goal is to establish an umbilical cord blood mononuclear cell (UCBMNC) bank to provide lifesaving and cellular products to treat millions of patients. MonoTx™ will use UCBMNC and other UCB components to treat spinal cord injury, stroke, macular degeneration, and other diseases.